B. Riley Securities Initiates Coverage On Cytokinetics with Buy Rating, Announces Price Target of $66
Portfolio Pulse from Benzinga Newsdesk
B. Riley Securities has initiated coverage on Cytokinetics (NASDAQ:CYTK) with a Buy rating and a price target of $66.
November 07, 2023 | 7:10 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Cytokinetics has received a Buy rating from B. Riley Securities with a price target of $66.
The Buy rating and price target of $66 from B. Riley Securities is a positive signal for Cytokinetics. This could lead to increased investor interest and potentially a rise in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100